Cargando…

Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report

BACKGROUND: There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now. CASE SUMMARY: In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Shu-Ying, Yuan, Jin, Lv, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649564/
https://www.ncbi.nlm.nih.gov/pubmed/36387802
http://dx.doi.org/10.12998/wjcc.v10.i31.11617
Descripción
Sumario:BACKGROUND: There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now. CASE SUMMARY: In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate antigen 15-3 (CA15-3) and carbohydrate antigen 72-4 (CA72-4) gradually returned to normal. CONCLUSION: Immunotherapy combined with chemotherapy in advanced-stage LELC may be more effective than immunotherapy or chemotherapy alone. CA15-3 and CA72-4 are biomarkers for evaluating therapeutic effects for LELC.